536565
TRIMURTHI
Start SIP
Invest Now
Start SIP in TRIMURTHI
Performance
- Low
- ₹60
- High
- ₹64
- 52 Week Low
- ₹25
- 52 Week High
- ₹70
- Open Price₹63
- Previous Close₹63
- Volume5,214
- 50 DMA₹59.31
- 100 DMA₹55.18
- 200 DMA₹46.60
Investment Returns
- Over 1 Month + 16.86%
- Over 3 Month + 6.46%
- Over 6 Month + 49.18%
- Over 1 Year + 140.63%
Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!
Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 58.8
- PEG Ratio
- 0.1
- Market Cap Cr
- 108
- P/B Ratio
- 3.7
- Average True Range
- 3.94
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 1.19
- RSI
- 50.61
- MFI
- 66.75
Novelix Pharmaceuticals Financials
Novelix Pharmaceuticals Technicals
EMA & SMA
Current Price
₹61.00
-1.96
(-3.11%)
- Bearish Moving Average 7
- Bullish Moving Average 9
- 20 Day
- ₹61.34
- 50 Day
- ₹59.31
- 100 Day
- ₹55.18
- 200 Day
- ₹46.60
Resistance and Support
61.75
- R3 67.67
- R2 65.93
- R1 63.49
- S1 59.31
- S2 57.57
- S3 55.13
Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-12 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-14 | Quarterly Results & A.G.M. | |
| 2025-06-24 | Others | Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company. |
| 2025-05-27 | Audited Results |
Novelix Pharmaceuticals F&O
About Novelix Pharmaceuticals
- NSE Symbol
- TRIMURTHI
- BSE Symbol
- 536565
- ISIN
- INE314I01036
Similar Stocks to Novelix Pharmaceuticals
Novelix Pharmaceuticals FAQs
Novelix Pharmaceuticals share price is ₹61 As on 22 February, 2026 | 14:20
The Market Cap of Novelix Pharmaceuticals is ₹107.5 Cr As on 22 February, 2026 | 14:20
The P/E ratio of Novelix Pharmaceuticals is 58.8 As on 22 February, 2026 | 14:20
The PB ratio of Novelix Pharmaceuticals is 3.7 As on 22 February, 2026 | 14:20
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.